Newsreels

Stay up to date on important research from major hematology/oncology meetings. Our expert APs discuss their top picks in a particular disease state, with a focus on what's most important in advanced practice.

Newsreels Myeloproliferative Neoplasms SOHO 2025 Annual Meeting

BET Inhibitor Plus Ruxolitinib in JAK Inhibitor-Naive Patients With MF

Sarah Profitt, PharmD, BCOP, reviews follow-up efficacy and safety from the phase III MANIFEST-2 trial, which evaluated the BET inhibitor pelabresib plus the JAK inhibitor ruxolitinib among patients with myelofibrosis (MF) who had not re...

October 28, 2025

Newsreels Myeloproliferative Neoplasms SOHO 2025 Annual Meeting

Thrombocytopenic MF: Pacritinib vs Momelotinib

Sarah Profitt, PharmD, BCOP, discusses data from a matching adjusted indirect treatment comparison of pacritinib and momelotinib for patients with thrombocytopenic myelofibrosis (MF). The study authors found that pacritinib outperformed ...

October 28, 2025

Newsreels Myeloproliferative Neoplasms SOHO 2025 Annual Meeting

A Subgroup Analysis From SIMPLIFY-1

Sarah Profitt, PharmD, BCOP, talks about clinical outcomes seen with momelotinib compared to ruxolitinib in patients with myelofibrosis and moderate anemia; findings were generally consistent with the intention-to-treat population of the...

October 28, 2025

Newsreels Breast Cancer 2025 ASCO Annual Meeting

How Does Hyperglycemia Affect Treatment for Prediabetic/Obese Patients With Breast Cancer?

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, discusses data from an analysis of prediabetic/obese patients with hormone receptor (HR)-postive, HER2-negative locally advanced/metastatic breast cancer. These patients received inavo...

July 1, 2025

Newsreels Breast Cancer 2025 ASCO Annual Meeting

How Do Body Weight and Composition Affect the Efficacy of CDK4/6 Inhibitors for ER+/HER2- Metastatic Breast Cancer?

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, reviews findings from a single-center retrospective analysis on how body composition measures—such as total fat, visceral fat, subcutaneous fat, skeletal muscle area, skeletal mus...

July 1, 2025

Newsreels Breast Cancer 2025 ASCO Annual Meeting

Metastatic HR+, HER2– Advanced Breast Cancer: Treating Patients With a PIK3CA Mutation With an Inavolisib-Based Regimen

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, reviews new data from the INAVO120 study presented at the 2025 ASCO Annual Meeting—the final overall survival analysis and updated results on safety, efficacy, and toxicity. INAVO120 is a p...

July 1, 2025

Newsreels Symptom Management 2024 ASH Annual Meeting & Exposition

GVHD Prophylaxis: Ruxolitinib and De-escalated PTCy for Older Patients

Katie Sellers, MPAS, PA-C, discusses a phase II trial presented at the ASH Annual Meeting exploring de-escalated post-transplant cyclophosphamide (PTCy) with ruxolitinib for GVHD prophylaxis in older patients undergoing reduced intensity...

December 26, 2024

Newsreels Symptom Management 2024 ASH Annual Meeting & Exposition

PTCy is Standard of Care: Improved GVHD Control and Survival in Older Patients

Katie Sellers, MPAS, PA-C, considers a post-hoc analysis focusing on transplant recipients aged ≥70 years in the BMT CTN 1703 trial (Abstract 1042). The study found that even in this older, frailer sub-population, post-transplant cycloph...

December 26, 2024

Newsreels Symptom Management 2024 ASH Annual Meeting & Exposition

Axatilimab for Chronic Graft-vs.-Host Disease

Katie Sellers, MPAS, PA-C, reviews findings from the Agave-201 study presented at the ASH Annual Meeting, which evaluated axatilimab, an anti-CSF1R monoclonal antibody, in chronic graft-versus-host disease (Abstract 98). Axatilimab showe...

December 23, 2024

Newsreels Myeloproliferative Neoplasms 2024 ASH Annual Meeting & Exposition

Burdens and QOL Impacts of Anemia and Transfusion Dependence in Myelofibrosis

Lindsey E. Kalhagen, MMS, PA-C, discusses a multinational, cross-sectional, online survey study (N = 155) that expanded on previous findings that 20 participants with myelofibrosis (MF) reported, in a series of elicitation interviews, su...

December 19, 2024

Newsreels Myeloproliferative Neoplasms 2024 ASH Annual Meeting & Exposition

Combination Interferon and Ruxolitinib vs Ruxolitinib in Myelofibrosis

Lindsey E. Kalhagen, MMS, PA-C, discusses a single-center, retrospective, propensity-score matched study that compared clinical response, progression-free survival (PFS) and overall survival (OS) outcomes, and adverse events in 62 patien...

December 19, 2024

Newsreels Myeloproliferative Neoplasms 2024 ASH Annual Meeting & Exposition

Table of Contents Archive

JADPRO Newsreels

BET Inhibitor Plus Ruxolitinib in JAK Inhibitor-Naive Patients With MF

Thrombocytopenic MF: Pacritinib vs Momelotinib

A Subgroup Analysis From SIMPLIFY-1

How Does Hyperglycemia Affect Treatment for Prediabetic/Obese Patients With Breast Cancer?

How Do Body Weight and Composition Affect the Efficacy of CDK4/6 Inhibitors for ER+/HER2- Metastatic Breast Cancer?

Metastatic HR+, HER2– Advanced Breast Cancer: Treating Patients With a PIK3CA Mutation With an Inavolisib-Based Regimen

GVHD Prophylaxis: Ruxolitinib and De-escalated PTCy for Older Patients

PTCy is Standard of Care: Improved GVHD Control and Survival in Older Patients

Axatilimab for Chronic Graft-vs.-Host Disease

Burdens and QOL Impacts of Anemia and Transfusion Dependence in Myelofibrosis

Combination Interferon and Ruxolitinib vs Ruxolitinib in Myelofibrosis

Real-World Outcomes of Momelotinib as a Therapy Option in Myelofibrosis Patients With Anemia

Current Issue

JADPRO Live 2025 United in Care

Assessment of Standards of Care for Oral Chemotherapy by Pharmacists in Clinical Settings

Advanced Practice Provider Led Trials in Radiation Oncology Are We Missing the Opportunity

Recent Issues

Issues

Sections

Solid Tumors

Hematologic Malignancies

Issues in Oncology

Supportive Care

Developmental Therapeutics

Live Events

Webinars

Conference Coverage

Educational Resources

JADPRO Newsreels

Current Issue

Recent Issues